Market Insights

According to the latest reports published by Market Research Future Reports, the global oral thin film drugs market is all set to expand at a CAGR of 8.10% from during forecast period. Oral drug delivery considered as an essential part of drug delivery and pharmaceutical industry. Patients with dysphagia (which means difficulty in swallowing) require oral administration of drugs. Thus, oral thin film medication is established for a smooth swallow of medicines than capsules or tablets. The fast dissolving medicines are a better alternative than capsules, syrups, and tablets. These drugs are beneficial for patients on the go or patients with swallowing problems. To improve patient compliance various types of vaccines and hormones, the market players are continually making developments in this field, which is, in turn, contributing tremendously to the global oral thin film drugs market to rise in the years to come. 

The sharp rise in the oral thin film drugs market Size is noticed in the numbers of the elderly population, where the demands of it are likely to evoke 2018 to 2023 (forecast period). The pharmaceutical companies and the manufacturers are actively carrying out tremendous research and development to switch from their existing drugs to the fast-dissolving oral thin films drugs. This factor is also highly valuing the market in the years to come with substantial proliferation rate. 

Key Players

Some prominent players in the oral thin film drugs market include Johnson Johnson Services, Inc. (U.S.), Pfizer Inc. (U.S.), CURE Pharmaceutical (U.S.), Novartis AG (Switzerland), LTS Lohmann Therapie-Systeme AG (Germany), GlaxoSmithKline Plc (U.K.), and Indivior Plc (U.S.).

Segmental Overview

According to the research done by Market Research Future Reports, the global oral thin film market has been segmented by product, disease indication, and distribution channel. 

By the mode of product, the market is categorized into sublingual and fast dissolving buccal film. 

By the mode of disease indication, the market is segmented into opioid dependence, migraine, schizophrenia, and nausea and vomiting, and others. 

By the mode of distribution channel in the report includes hospital pharmacies, retail pharmacies, online drug stores, and others. 

Regional Analysis

In the reports of MRFR, geographically the oral thin film drugs market is analyzed among essential regions such as Americas, Europe, Asia Pacific (APAC), and the Middle East Africa. 

Among these, the Americas accounts the lion's share of the market in 2017 owing to the factors such as the existence of well-known players in the healthcare sector, increased healthcare expenditure of nations such as the U.S., as well as sophisticated healthcare expenditure. 

Then comes the European oral thin film drugs market, which is also expanding at a higher CAGR over the forecast period owing to some supportive government healthcare funds that are helping the patients to overcome diseases. The strong economies of France, Germany, and the U.K. generally contribute to market revenue, which will extend until 2023 as well.